The proliferation of enhancement technologies and pharmacological agents has perpetuated the view of American doctors and patients of medical care as a market commodity driven by what consumers want and are willing to pay for.
Posthumous fatherhood and postmenopausal motherhood raise a multitude of legal, ethical, and social concerns that the law and regulatory agencies have not been able to adequately address to date.
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
This article asks whether the benefits of neuroelectronic devices that restore function outweigh their risks to the individual and society and whether we should move beyond therapy to enhance our capabilities by the use of such devices?
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
In “Ethics of International Research: What Does Responsiveness Mean?” Christine Grady explains how developing countries are vulnerable to exploitation by researchers and explores what “responsiveness” to the needs of those populations might entail.
Argument that physicians called upon for expert testimony in court have an ethical duty to educate the jury by offering opinions based upon published, clinically based evidence and peer-reviewed medical literature.